PGDx, Mayo Clinic to collaborate
BALTIMORE—A strategic collaboration is underway between Personal Genome Diagnostics Inc. (PGDx) and Mayo Clinic to further develop clinical diagnostic solutions for oncology, working on optimizing technologies and clinical utility studies for liquid biopsy and tissue-based genomic applications. Specific details were not released, but the collaboration will focus on targetable genomic alterations and advancing oncology diagnostics testing.
“We are proud to enter into this strategic collaboration with Mayo Clinic. Their deep knowledge of establishing standards of care in oncology, the complexity and volume of cancer cases they see, and their expertise in the implementation of testing in a real-world setting are second to none,” said Doug Ward, CEO of PGDx. “As we continue our quest to empower the fight against cancer, collaborating with Mayo Clinic will allow us to better assess the impact that our elio liquid biopsy and tissue applications will have on improving clinical insights, and will advance innovations in next-generation sequencing technology.”